Madrigal maestro phase 3 nash trials continue without protocol modifications; new data demonstrate that reductions in liver fat achieved by resmetirom predict nash resolution and fibrosis reduction

-- maestro phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the covid pandemic.
MDGL Ratings Summary
MDGL Quant Ranking